Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Get Data
    • Macro-Economic News
    • Research Analysis
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Get Data
    • Macro-Economic News
    • Research Analysis
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
Nairametrics
No Result
View All Result
Home Business News Coronavirus

Oxford’s COVID-19 vaccine may be mass produced in 2020

Chike Olisah by Chike Olisah
July 21, 2020
in Coronavirus
Oxford COVID-19 vaccine
Share on FacebookShare on TwitterShare on Linkedin

The lead developer for the University of Oxford’s COVID-19 vaccine, Sarah Gilbert, has revealed that the vaccine could be rolled out by the end of the year but there is no certainty.

The Oxford experimental vaccine which is done in collaboration with AstraZeneca produced an immune response in early-stage clinical trials with no major side effect, according to data that was displayed on Monday. This development provides the hope that it could be in use before the end of the year.

According to report from Reuters, Sarah Gilbert in her discussion with BBC Radio said, ‘’The end of the year target for getting vaccine rollout, it’s a possibility but there’s absolutely no certainty about that because we need three things to happen.”

RelatedPosts

FG says Nigeria gathering vaccine producers to develop technology in case of future outbreaks

You can now go to United States without COVID-19 tests

READ MORE: Global air passenger slump to persist till 2023 – Moody’s

Sarah Gilbert pointed out that it needed to be shown to work at the late-stage trials, there needed to be large quantities manufactured and regulators had to agree quickly to license it for emergency use.

“All of these three things have to happen and come together before we can start seeing large numbers of people vaccinated,” she said.

Backstory: Nairametrics yesterday reported that a vaccine trial for the COVID-19 disease by a joint team of University of Oxford researchers and pharmaceutical firm, AstraZeneca Plc showed strong immune response in early testings with humans.

READ ALSO: Pfizer’s COVID-19 vaccine shows positive results

The trials also showed protective neutralization of antibodies and immune t-cells aimed at the virus. Oxford’s Chief of Jenner Institute, Adrian Hill, said the research has recorded good immune system responses with no serious side effect.

The Oxford scientists are hoping that 1 million doses of the potential COVID-19 vaccine would be produced by September this year.

Although the agreement had been reached with AstraZeneca for the manufacturing of the vaccine, the lower prevalence of the novel coronavirus in Britain has complicated the process of proving its efficacy.

Late-stage trials are currently going on in Brazil and South Africa and are due to start in the United States.

Related

Tags: Covid-19OxfordSarah GilbertVaccine

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Mega Millions
Hot forex
Cornerstone
Polaris Bank
Access Bank
Bankers Committee
First bank


FCMB
Ikeja Electrics




    Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |

    Recent News

    • JP Morgan warns that oil prices could surge to $380 a barrel
    • Buhari says Lekki Deep Sea Port to create job opportunities, facilitate trade
    • Weekly Stock Update: Nigerian Exchange Group record gains, up 0.24% w-o-w

    Follow us on social media:

    Recent News

    reserves, Nigeria Crude Oil Prices, Nigeria wants international oil companies to pay up now , Trade conflict between United States, China continues to affect oil prices, Global oil prices rally to $69.16, as Soleimani killed in US air strike, Crude oil prices continue to rise on the backdrop of US-Iran tension, Coronavirus projected to affect crude oil demand negatively , Worry, as Coronavirus threat pushes oil price below budget benchmark, Coronavirus: FG to review budget as oil price plunges, BOOM: Crude oil price crash below $30 in worst trading day since 1930,Bears ravage Global market, Brent Oil surges 10% trading at $27.29 per barrel, Crude Oil up 10% as Brent crude raises to $27 per barrel, Oil market crisis – possible production shutdown looms, The time crude oil became cheaper than water,, Brent crude surges past $40, analyst recommends investment in crude oil derivatives, Nigeria's Bonny light hit four months high, Nigeria's Bonny light hit four months high

    JP Morgan warns that oil prices could surge to $380 a barrel

    July 2, 2022
    Buhari says Lekki Deep Sea Port to create job opportunities, facilitate trade

    Buhari says Lekki Deep Sea Port to create job opportunities, facilitate trade

    July 2, 2022
    • ABOUT US
    • CONTACT US
    • PRODUCTS
    • ANDROID APP
    • iOS APP
    • DISCLAIMER
    • CAREERS
    • PRIVACY POLICY

    © 2022 Nairametrics

    No Result
    View All Result
    • Home
    • Exclusives
      • Financial Analysis
      • Corporate Stories
      • Interviews
      • Investigations
      • Metrics
    • Markets
      • Cryptos
      • Commodities
      • Equities
        • Dividends
        • Stock Market
      • Fixed Income
      • Market Views
      • Securities
    • Industries
      • Company News
      • Consumer Goods
      • Content Partners
      • Corporate deals
      • Corporate Press Releases
      • Energy
      • Entertainment
      • Financial Services
      • Hospitality & Travel
      • Manufacturing
      • Real Estate and Construction
      • Tech News
    • Economy
      • Get Data
      • Macro-Economic News
      • Research Analysis
    • Business News
    • Financial Literacy
      • Career tips
      • Personal Finance
    • Lifestyle
      • Billionaire Watch
      • Profiles
    • Opinions
      • Blurb
      • Op-Eds

    © 2022 Nairametrics

    Social Media Auto Publish Powered By : XYZScripts.com